Icatibant Acetate

醋酸艾替班特

Report date: 2022/05/18 12:02:02
NMEFirst In Class

Base Information

Drug NameIcatibant Acetate
Drug Alias NameIcatibant醋酸伊卡替班艾替班特IcatibantoIcatibantum +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBradykinin B2 receptor antagonists
TargetsBradykinin B2 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)InflammationMitochondrial Diseases +[7] 
Global Approved IndicationsAngioedemas, Hereditary
Approved Indications in ChinaAngioedemas, Hereditary
Original Approved Country/TerritoryEU
Original Approved Date2008/07/11
Country/TerritoryCzechiaCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShire Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals USA IncQueen'S University BelfastShire Pharmaceuticals +[5] 
Inactive CompaniesShireJerini AgSanofi +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)HypotensionAngioedemas, Hereditary
Inactive IndicationsInflammationMitochondrial DiseasesAngioedema +[4] 

Other Information

ATC CodeB06AC02
Related LinksWikipediaDrugBankKEGG